EL7.AI
StocksMedium•17 November 2026•
4 min read

NEXGEL Posts $2.28 Per-Share Loss as Third-Quarter Profit Margin Declines

Key Facts

1Diluted loss per share was $2.28 in the third quarter of 2026, compared with $1.64 in the year-earlier period.
2Net revenue rose 8.4% to $3.179 million in the third quarter.
3Gross margin fell to 35.4% from 42.4% year over year.
4Net loss attributable to NEXGEL shareholders was about $1.11 million, compared with $653 thousand in the third quarter of 2025.
5Unrestricted cash was $278 thousand on September 30, 2026.

NEXGEL posted a diluted loss of $2.28 per share for the three months ended September 30, 2026, compared with a loss of $1.64 in the year-earlier period, according to its quarterly report filed with the U.S. Securities and Exchange Commission on November 16. The report showed higher net revenue alongside lower gross profit and a wider loss, reflecting pressure on profitability despite sales growth. The net loss attributable to the company's shareholders was $1.11 million, compared with $653 thousand a year earlier. NEXGEL retroactively adjusted its per-share figures to reflect a 1-for-20 reverse stock split that took effect on October 12. NXGL shares closed at $3.93 on the November 16 session, according to EL7 data.

Net revenue in the third quarter rose to $3.179 million from $2.934 million, an 8.4% year-over-year increase, the report said. The company attributed the increase to $881 thousand in revenue from new biomaterials products. That growth was partly offset by a $442 thousand decline in branded consumer products revenue and a $171 thousand decline in contract manufacturing revenue compared with the same period last year. The company disclosed that these shifts among product categories shaped the quarter's revenue mix. Sales growth therefore did not translate into higher gross profit, which fell to $1.125 million from $1.243 million.

Gross margin fell to 35.4% in the third quarter from 42.4% a year earlier. NEXGEL attributed the decline to initial sales of biomaterials products carrying lower margins, as well as higher inventory write-offs, shipping costs and royalties. The new products thus contributed to revenue growth but began with lower margins, according to the company's explanation. Lower gross profit, combined with higher expenses, flowed through to the bottom line. Pressure was not limited to revenue or product costs; selling, general and administrative expenses rose to $3.664 million from $1.961 million, an 86.8% year-over-year increase.

NEXGEL said selling, general and administrative expenses included $702 thousand to establish and operate BioNx Surgical, as well as $1.134 million in amortization of an intangible asset related to the Celularity license. For the first nine months of 2026, these expenses rose to $9.277 million from $5.820 million in the same period of 2025. Over the same period, revenue increased to $9.515 million from $8.625 million, a 10.3% gain. The company said biomaterials product sales contributed $1.695 million to revenue for the nine months, while a $730 thousand decline in branded consumer products revenue offset part of the increase. The comparison between revenue growth and rising expenses highlights a widening gap between business expansion and profitability.

The company's net loss for the nine months ended September 30, 2026, was about $5.572 million, compared with $1.965 million in the same period of 2025. The loss attributable to NEXGEL shareholders was $5.676 million, compared with $2.030 million a year earlier. On liquidity, the company reported $658 thousand in cash and restricted cash at the end of September, of which $278 thousand was unrestricted. The company used $5.124 million in cash in operating activities during the first nine months of the year. These figures place limited liquidity in the context of rising losses and operating cash use during the period.

NEXGEL said its financial condition raises substantial doubt about its ability to continue as a going concern, and that the conversion of notes and proposed merger do not alleviate that doubt for one year from the issuance of the financial statements. The company wrote: "We expect to continue to incur losses in the near future." It added that its long-term continuation depends on managing and growing its existing products and ultimately achieving profitable operations. The company thus linked its outlook for continuing operations to its ability to grow its products and achieve profitability, while acknowledging that losses are expected to continue in the near future. It filed its quarterly report on November 16, 2026.

Open on chart